Health systems need to use the new tools to address RSV, a leading cause of baby hospitalisations
From being a largely unknown pathogen, Respiratory Syncytial Virus (RSV) is now almost a household word – and a fearful one for families with infants and young children at risk. But new solutions, such as long-acting monoclonal antibodies (mAbs) and maternal vaccination, both recently recommended by the World Health Organization (WHO), could dramatically alter the […]
Continue reading ->
Health Policy Watch. (2024, December 8). New tools to address RSV, a leading cause of baby hospitalisations. Health Policy Watch. https://healthpolicy-watch.news/new-tools-to-address-rsv-a-leading-cause-of-baby-hospitalisations/
Related news
Recruitment milestone achieved in important Phase II study in Alzheimer’s Disease
Julius Clinical are proud to announce the successful completion of recruitment for the PRImus-AD study, a clinical Phase II study which investigates the safety and efficacy of the drug candidate PRI-002 for the treatment of Alzheimer's Disease....
Unlocking the Power of Real-World Evidence: When to Use It, How to Frame Your Research, and Key Limitations to Consider
11 February 2025Professor Rick Grobbee, Professor of Clinical Epidemiology at the Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht (the Netherlands), and Chief Scientific Officer at Julius Clinical, (Academ...
Julius Clinical, a founding sponsor of Bio-Neuroscience 2025
Julius Clinical is proud to announce our continued sponsorship of Bio-Neuroscience 2025, the premier summit for CEOs, investors, and industry decision-makers in CNS neuroscience drug development.Taking place in Amsterdam from 25-27 February 20...